Tailoring inorganic nanoadjuvants towards next-generation vaccines.

Vaccines, one of the most effective and powerful public health measures, have saved countless lives over the past century and still have a tremendous global impact. As an indispensable component of modern vaccines, adjuvants play a critical role in strengthening and/or shaping a specific immune response against infectious diseases as well as malignancies. The application of nanotechnology provides the possibility of precisely tailoring the building blocks of nanoadjuvants towards modern vaccines with the desired immune response. The last decade has witnessed great academic progress in inorganic nanomaterials for vaccine adjuvants in terms of nanometer-scale synthesis, structure control, and functionalization design. Inorganic adjuvants generally facilitate the delivery of antigens, allowing them to be released in a sustained manner, enhance immunogenicity, deliver antigens efficiently to specific targets, and induce a specific immune response. In particular, the recent discovery of the intrinsic immunomodulatory function of inorganic nanomaterials further allows us to shape the immune response towards the desired type and increase the efficacy of vaccines. In this article, we comprehensively review state-of-the-art research on the use of inorganic nanomaterials as vaccine adjuvants. Attention is focused on the physicochemical properties of versatile inorganic nanoadjuvants, such as composition, size, morphology, shape, hydrophobicity, and surface charge, to effectively stimulate cellular immunity, considering that the clinically used alum adjuvants can only induce strong humoral immunity. In addition, the efforts made to date to expand the application of inorganic nanoadjuvants in cancer vaccines are summarized. Finally, we discuss the future prospects and our outlook on tailoring inorganic nanoadjuvants towards next-generation vaccines.

[1]  Y. Hayashi,et al.  An immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis, Z-100, restores the balance of Th1/Th2 cell responses in tumor bearing mice. , 1999, Immunology letters.

[2]  D. Tambourgi,et al.  Immunological parameters related to the adjuvant effect of the ordered mesoporous silica SBA-15. , 2010, Vaccine.

[3]  Dean Ho,et al.  Cancer Nanomedicine: From Drug Delivery to Imaging , 2013, Science Translational Medicine.

[4]  Paul Richman,et al.  Aluminum salts in vaccines--US perspective. , 2002, Vaccine.

[5]  Gerd Ritter,et al.  PEGylated gold nanoparticles conjugated to monoclonal F19 antibodies as targeted labeling agents for human pancreatic carcinoma tissue. , 2008, ACS nano.

[6]  S. Kanoni,et al.  In vitro and in vivo effects of zinc on cytokine signalling in human T cells , 2008, Experimental Gerontology.

[7]  J. Buer,et al.  The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. , 2010, Biomaterials.

[8]  N. Mitter,et al.  Mesoporous silica nanoparticles act as a self-adjuvant for ovalbumin model antigen in mice. , 2013, Small.

[9]  C. Hunter,et al.  Aluminium hydroxide adjuvant initiates strong antigen-specific Th2 responses in the absence of IL-4- or IL-13-mediated signaling. , 1999, Journal of immunology.

[10]  R. Serda Particle platforms for cancer immunotherapy , 2013, International journal of nanomedicine.

[11]  Jayanth Panyam,et al.  Dynamics of Endocytosis and Exocytosis of Poly(D,L-Lactide-co-Glycolide) Nanoparticles in Vascular Smooth Muscle Cells , 2003, Pharmaceutical Research.

[12]  Martin L. Miller,et al.  Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.

[13]  S. Samman,et al.  Zinc and Regulation of Inflammatory Cytokines: Implications for Cardiometabolic Disease , 2012, Nutrients.

[14]  M. J. Sawkins,et al.  The shape and size of hydroxyapatite particles dictate inflammatory responses following implantation , 2017, Scientific Reports.

[15]  Zhengrong Cui,et al.  Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses , 2010, Expert review of vaccines.

[16]  R. Flavell,et al.  NLRP3 inflammasome plays a critical role in the pathogenesis of hydroxyapatite-associated arthropathy , 2011, Proceedings of the National Academy of Sciences.

[17]  Bengt Fadeel,et al.  Efficient internalization of silica-coated iron oxide nanoparticles of different sizes by primary human macrophages and dendritic cells. , 2011, Toxicology and applied pharmacology.

[18]  C. Zhi,et al.  Identification of a boron nitride nanosphere-binding peptide for the intracellular delivery of CpG oligodeoxynucleotides. , 2012, Nanoscale.

[19]  Marco Zanella,et al.  Biological applications of gold nanoparticles. , 2008, Chemical Society reviews.

[20]  Jun Lin,et al.  Functionalized mesoporous silica materials for controlled drug delivery. , 2012, Chemical Society reviews.

[21]  J. Brewer,et al.  Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro , 2012, Immunology letters.

[22]  Rajesh K. Gupta,et al.  Adjuvants--a balance between toxicity and adjuvanticity. , 1993, Vaccine.

[23]  Jianlin Shi,et al.  One-pot synthesis of magnetic and mesoporous bioactive glass composites and their sustained drug release property , 2008 .

[24]  P. Sharma,et al.  The future of immune checkpoint therapy , 2015, Science.

[25]  V. Kanchan,et al.  Interactions of antigen-loaded polylactide particles with macrophages and their correlation with the immune response. , 2007, Biomaterials.

[26]  C. Fan,et al.  Polyvalent immunostimulatory nanoagents with self-assembled CpG oligonucleotide-conjugated gold nanoparticles. , 2012, Angewandte Chemie.

[27]  A. Verma,et al.  Zinc oxide nanoparticles provide an adjuvant effect to ovalbumin via a Th2 response in Balb/c mice. , 2014, International immunology.

[28]  Richard A Flavell,et al.  Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy. , 2012, Nature materials.

[29]  S. Gabrielsson,et al.  Mesoporous silica particles potentiate antigen-specific T-cell responses. , 2014, Nanomedicine.

[30]  Xuebin Wang,et al.  Multimodal luminescent-magnetic boron nitride nanotubes@NaGdF₄:Eu structures for cancer therapy. , 2014, Chemical communications.

[31]  E. Relyveld,et al.  Calcium phosphate adjuvanted allergens. , 1985, Annals of allergy.

[32]  P. Marrack,et al.  Towards an understanding of the adjuvant action of aluminium , 2009, Nature Reviews Immunology.

[33]  M. Kronenberg,et al.  Vα14i NKT Cells Are Innate Lymphocytes That Participate in the Immune Response to Diverse Microbes , 2005, Journal of Clinical Immunology.

[34]  D. Katz,et al.  Hapten-specific IgE antibody responses in mice. I. Secondary IgE responses in irradiated recipients of syngeneic primed spleen cells. , 1973 .

[35]  R. Mumper,et al.  Nanotemplate Engineering of Cell Specific Nanoparticles , 2003 .

[36]  Lili Qin,et al.  The use of layered double hydroxides as DNA vaccine delivery vector for enhancement of anti-melanoma immune response. , 2011, Biomaterials.

[37]  Zoraida P. Aguilar,et al.  Iron oxide nanoparticles as a clinically acceptable delivery platform for a recombinant blood‐stage human malaria vaccine , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[38]  T. Kündig,et al.  Antigen kinetics determines immune reactivity , 2008, Proceedings of the National Academy of Sciences.

[39]  Dan Peer,et al.  Nanoparticle hydrophobicity dictates immune response. , 2012, Journal of the American Chemical Society.

[40]  Jianlin Shi,et al.  Hollow‐Structured Mesoporous Materials: Chemical Synthesis, Functionalization and Applications , 2014, Advanced materials.

[41]  Haitao Jiang,et al.  Enhanced mucosal and systemic immune responses obtained by porous silica nanoparticles used as an oral vaccine adjuvant: effect of silica architecture on immunological properties. , 2012, International journal of pharmaceutics.

[42]  Sudipta Seal,et al.  Exposure to titanium dioxide nanomaterials provokes inflammation of an in vitro human immune construct. , 2009, ACS nano.

[43]  Y. Bando,et al.  Hollow boron nitride nanospheres as boron reservoir for prostate cancer treatment , 2017, Nature Communications.

[44]  Xia Li,et al.  Synergistic effects of stellated fibrous mesoporous silica and synthetic dsRNA analogues for cancer immunotherapy. , 2018, Chemical communications.

[45]  S. Yoshino,et al.  Adjuvant effect of zinc oxide on Th2 but not Th1 immune responses in mice , 2010, Immunopharmacology and immunotoxicology.

[46]  I. Toth,et al.  Modern Subunit Vaccines: Development, Components, and Research Opportunities , 2013, ChemMedChem.

[47]  Agula Bo,et al.  Magnesium sulfate induced toxicity in vitro in AGS gastric adenocarcinoma cells and in vivo in mouse gastric mucosa. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[48]  A. Oyane,et al.  Effect of coprecipitation temperature on the properties and activity of fibroblast growth factor-2 apatite composite layer , 2009 .

[49]  Kenneth J. Dart,et al.  Adjuvanticity and toxicity of cobalt oxide nanoparticles as an alternative vaccine adjuvant. , 2012, Nanomedicine.

[50]  Daejin Kim,et al.  Imageable antigen-presenting gold nanoparticle vaccines for effective cancer immunotherapy in vivo. , 2012, Angewandte Chemie.

[51]  S. Kaufmann,et al.  Challenges and responses in human vaccine development. , 2014, Current opinion in immunology.

[52]  Byeong-Cheol Ahn,et al.  Radionuclide-embedded gold nanoparticles for enhanced dendritic cell-based cancer immunotherapy, sensitive and quantitative tracking of dendritic cells with PET and Cerenkov luminescence , 2016 .

[53]  A. Taniguchi,et al.  Mesoporous Caged‐γ‐AlOOH‐Double‐Stranded RNA Analog Complexes for Cancer Immunotherapy , 2018 .

[54]  J L Pedraz,et al.  Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanospheres. , 2002, Vaccine.

[55]  Jianlin Shi,et al.  In Vivo Bio‐Safety Evaluations and Diagnostic/Therapeutic Applications of Chemically Designed Mesoporous Silica Nanoparticles , 2013, Advanced materials.

[56]  O. Finn The dawn of vaccines for cancer prevention , 2017, Nature Reviews Immunology.

[57]  Dmitri Golberg,et al.  Boron nitride nanotubes functionalized with mesoporous silica for intracellular delivery of chemotherapy drugs. , 2013, Chemical communications.

[58]  Stefan Tenzer,et al.  Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology. , 2013, Nature nanotechnology.

[59]  C. Coban,et al.  Silica crystals and aluminum salts regulate the production of prostaglandin in macrophages via NALP3 inflammasome-independent mechanisms. , 2011, Immunity.

[60]  Xia Li,et al.  Rod-shaped and fluorine-substituted hydroxyapatite free of molecular immunopotentiators stimulates anti-cancer immunity in vivo. , 2016, Chemical communications.

[61]  A. Harandi,et al.  Vaccine adjuvants: scientific challenges and strategic initiatives , 2009, Expert review of vaccines.

[62]  María Vallet-Regí,et al.  Mesoporous materials for drug delivery. , 2007, Angewandte Chemie.

[63]  P. Swider,et al.  Adsorption and release of BMP-2 on nanocrystalline apatite-coated and uncoated hydroxyapatite/beta-tricalcium phosphate porous ceramics. , 2009, Journal of biomedical materials research. Part B, Applied biomaterials.

[64]  T. Roger,et al.  Basic Calcium Phosphate Crystals Induce Monocyte/Macrophage IL-1β Secretion through the NLRP3 Inflammasome In Vitro , 2011, The Journal of Immunology.

[65]  Gareth R. Williams,et al.  Immunity induced by a broad class of inorganic crystalline materials is directly controlled by their chemistry , 2014, The Journal of experimental medicine.

[66]  L. Ruff,et al.  Multivalent Porous Silicon Nanoparticles Enhance the Immune Activation Potency of Agonistic CD40 Antibody , 2012, Advanced materials.

[67]  Vasso Apostolopoulos,et al.  Pathogen recognition and development of particulate vaccines: does size matter? , 2006, Methods.

[68]  Jian Liang,et al.  Preparation of mesoporous calcium doped silica spheres with narrow size dispersion and their drug loading and degradation behavior , 2007 .

[69]  J. Coote,et al.  Protein coated microcrystals formulated with model antigens and modified with calcium phosphate exhibit enhanced phagocytosis and immunogenicity☆ , 2014, Vaccine.

[70]  J. Gutiérrez,et al.  Comparison of the adjuvant activity of aluminum hydroxide and calcium phosphate on the antibody response towards Bothrops asper snake venom , 2014, Journal of immunotoxicology.

[71]  J. Tschopp,et al.  Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica , 2008, Science.

[72]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[73]  K. Hidajat,et al.  Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix-drug interactions. , 2005, Langmuir : the ACS journal of surfaces and colloids.

[74]  J. Yewdell Designing CD8+ T cell vaccines: it's not rocket science (yet). , 2010, Current opinion in immunology.

[75]  Meiying Wang,et al.  Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles. , 2013, ACS nano.

[76]  Bin Wu,et al.  The enhanced immune response of hepatitis B virus DNA vaccine using SiO2@LDH nanoparticles as an adjuvant. , 2014, Biomaterials.

[77]  Chengtie Wu,et al.  Nanoporous microstructures mediate osteogenesis by modulating the osteo-immune response of macrophages. , 2017, Nanoscale.

[78]  M. Jaroniec,et al.  Ordered mesoporous silica SBA-15: a new effective adjuvant to induce antibody response. , 2006, Small.

[79]  Richard A. Flavell,et al.  Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants , 2008, Nature.

[80]  T. Hashimoto,et al.  A phase I study on combined therapy with proton-beam radiotherapy and in situ tumor vaccination for locally advanced recurrent hepatocellular carcinoma , 2013, Radiation Oncology.

[81]  D. Ciocca,et al.  A pilot study with a therapeutic vaccine based on hydroxyapatite ceramic particles and self-antigens in cancer patients , 2007, Cell stress & chaperones.

[82]  C. Traube,et al.  Immunotherapy with a calcium phosphate‐adsorbed five‐grass‐pollen extract in seasonal rhinoconjunctivitis: a double‐blind, placebo‐controlled study , 2001, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[83]  Bengt Fadeel,et al.  Efficient internalization of mesoporous silica particles of different sizes by primary human macrophages without impairment of macrophage clearance of apoptotic or antibody-opsonized target cells. , 2009, Toxicology and applied pharmacology.

[84]  M. Aronova,et al.  DNA-inorganic hybrid nanovaccine for cancer immunotherapy. , 2016, Nanoscale.

[85]  Katrin Schwarz,et al.  Nanoparticles target distinct dendritic cell populations according to their size , 2008, European journal of immunology.

[86]  P. Kupelian,et al.  Cerium oxide nanoparticles protect gastrointestinal epithelium from radiation-induced damage by reduction of reactive oxygen species and upregulation of superoxide dismutase 2. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[87]  A. Punnoose,et al.  The Influences of Cell Type and ZnO Nanoparticle Size on Immune Cell Cytotoxicity and Cytokine Induction , 2009, Nanoscale research letters.

[88]  T. Ohno,et al.  Comprehensive Mechanism Analysis of Mesoporous‐Silica‐Nanoparticle‐Induced Cancer Immunotherapy , 2016, Advanced healthcare materials.

[89]  D. Chaplin Overview of the immune response. , 2003, The Journal of allergy and clinical immunology.

[90]  Huizhi Guo,et al.  Immunization of mice by Hollow Mesoporous Silica Nanoparticles as carriers of Porcine Circovirus Type 2 ORF2 Protein , 2012, Virology Journal.

[91]  J. Blattman,et al.  Cancer Immunotherapy: A Treatment for the Masses , 2004, Science.

[92]  Soumen Das,et al.  Immunomodulation and T Helper TH1/TH2 Response Polarization by CeO2 and TiO2 Nanoparticles , 2013, PloS one.

[93]  Min Zhu,et al.  Mesoporous silica nanoparticles for enhancing the delivery efficiency of immunostimulatory DNA drugs. , 2014, Dalton transactions.

[94]  Youngjin Choi,et al.  The effect of surface modification of mesoporous silica micro-rod scaffold on immune cell activation and infiltration. , 2016, Biomaterials.

[95]  K. Schwarz,et al.  Long‐lived memory CD8+ T cells are programmed by prolonged antigen exposure and low levels of cellular activation , 2006, European journal of immunology.

[96]  T. Morcol,et al.  Calcium Phosphate Nanoparticles Induce Mucosal Immunity and Protection against Herpes Simplex Virus Type 2 , 2002, Clinical and Vaccine Immunology.

[97]  Derek T. O'Hagan,et al.  Recent Advances in Vaccine Adjuvants , 2002, Pharmaceutical Research.

[98]  Youngjin Choi,et al.  Injectable, spontaneously assembling inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy , 2014, Nature Biotechnology.

[99]  M. Guenounou,et al.  Importance of hydroxyapatite particles characteristics on cytokines production by human monocytes in vitro. , 2003, Biomaterials.

[100]  Huiying Zhu,et al.  Europium-doped mesoporous silica nanosphere as an immune-modulating osteogenesis/angiogenesis agent. , 2017, Biomaterials.

[101]  L. Peek,et al.  Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. , 2007, Journal of pharmaceutical sciences.

[102]  F. Baneyx,et al.  Just-in-time vaccines: Biomineralized calcium phosphate core-immunogen shell nanoparticles induce long-lasting CD8(+) T cell responses in mice. , 2014, Nanomedicine : nanotechnology, biology, and medicine.

[103]  T. Ohno,et al.  Pore size-dependent immunogenic activity of mesoporous silica-based adjuvants in cancer immunotherapy. , 2014, Journal of biomedical materials research. Part A.

[104]  Sudipta Seal,et al.  Anti-inflammatory properties of cerium oxide nanoparticles. , 2009, Small.

[105]  D. Dormont,et al.  Aluminum hydroxide adjuvant induces macrophage differentiation towards a specialized antigen-presenting cell type. , 2004, Vaccine.

[106]  Chengzhong Yu,et al.  Understanding the Effect of Surface Chemistry of Mesoporous Silica Nanorods on Their Vaccine Adjuvant Potency , 2017, Advanced healthcare materials.

[107]  J. Tschopp,et al.  Nanoparticles activate the NLR pyrin domain containing 3 (Nlrp3) inflammasome and cause pulmonary inflammation through release of IL-1α and IL-1β , 2010, Proceedings of the National Academy of Sciences.

[108]  K. Onuma,et al.  Mesoporous Silica‐Calcium Phosphate‐Tuberculin Purified Protein Derivative Composites as an Effective Adjuvant for Cancer Immunotherapy , 2013, Advanced healthcare materials.

[109]  Henk C. Hoogsteden,et al.  Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells , 2008, The Journal of experimental medicine.

[110]  Jun Jiao,et al.  Alpha-alumina nanoparticles induce efficient autophagy-dependent cross-presentation and potent antitumour response , 2011, Nature nanotechnology.

[111]  Mariagrazia Pizza,et al.  The Adjuvants Aluminum Hydroxide and MF59 Induce Monocyte and Granulocyte Chemoattractants and Enhance Monocyte Differentiation toward Dendritic Cells1 , 2008, The Journal of Immunology.

[112]  Rino Rappuoli,et al.  Alum adjuvanticity: Unraveling a century old mystery , 2008, European journal of immunology.

[113]  Maria Strømme,et al.  Mesoporous silica particles induce size dependent effects on human dendritic cells. , 2007, Nano letters.

[114]  T. Ohno,et al.  Stimulation of In Vivo Antitumor Immunity with Hollow Mesoporous Silica Nanospheres. , 2016, Angewandte Chemie.

[115]  A. Jarzab,et al.  [Subunit vaccines--antigens, carriers, conjugation methods and the role of adjuvants]. , 2013, Postepy higieny i medycyny doswiadczalnej.

[116]  M. Ferrari,et al.  Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. , 2015, Cell reports.

[117]  K. Onuma,et al.  Mesoporous bioactive glass coatings on stainless steel for enhanced cell activity, cytoskeletal organization and AsMg immobilization , 2010 .

[118]  Jie Zheng,et al.  Passive tumor targeting of renal-clearable luminescent gold nanoparticles: long tumor retention and fast normal tissue clearance. , 2013, Journal of the American Chemical Society.

[119]  A. Godec,et al.  Understanding controlled drug release from mesoporous silicates: theory and experiment. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[120]  Young Keun Kim,et al.  A multifunctional core-shell nanoparticle for dendritic cell-based cancer immunotherapy. , 2011, Nature nanotechnology.

[121]  D. Fearon,et al.  Arrested Differentiation, the Self-Renewing Memory Lymphocyte, and Vaccination , 2001, Science.

[122]  Jiye Shi,et al.  One‐Shot Immunomodulatory Nanodiamond Agents for Cancer Immunotherapy , 2016, Advanced materials.

[123]  Jeffrey B Ulmer,et al.  Targeting the innate immune response with improved vaccine adjuvants , 2005, Nature Medicine.

[124]  W. Li,et al.  Surface-engineered gold nanorods: promising DNA vaccine adjuvant for HIV-1 treatment. , 2012, Nano letters.

[125]  Hong-mei Xu Th1 cytokine-based immunotherapy for cancer. , 2014, Hepatobiliary & pancreatic diseases international : HBPD INT.

[126]  T. Morcol,et al.  Calcium Phosphate Nanoparticle Adjuvant , 2000, Clinical Diagnostic Laboratory Immunology.

[127]  D. Schrump,et al.  Whole-Cell Cancer Vaccines Induce Large Antibody Responses to Carbohydrates and Glycoproteins. , 2016, Cell chemical biology.

[128]  A. Prasad,et al.  Serum thymulin in human zinc deficiency. , 1988, The Journal of clinical investigation.

[129]  R. Drezek,et al.  In vivo gold nanoparticle delivery of peptide vaccine induces anti-tumor immune response in prophylactic and therapeutic tumor models. , 2015, Small.

[130]  Y. Yoshioka,et al.  The effect of surface modification of amorphous silica particles on NLRP3 inflammasome mediated IL-1beta production, ROS production and endosomal rupture. , 2010, Biomaterials.

[131]  Rogério Gaspar,et al.  Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking , 2014, Front. Chem..

[132]  K. Knutson,et al.  Tumor antigen-specific T helper cells in cancer immunity and immunotherapy , 2005, Cancer Immunology, Immunotherapy.

[133]  Takafumi Ninomiya,et al.  Gold nanoparticles as a vaccine platform: influence of size and shape on immunological responses in vitro and in vivo. , 2013, ACS nano.

[134]  H. Nauwynck,et al.  Inactivated virus vaccines from chemistry to prophylaxis: merits, risks and challenges , 2012, Expert review of vaccines.

[135]  K. Onuma,et al.  Zn- and Mg- Containing Tricalcium Phosphates-Based Adjuvants for Cancer Immunotherapy , 2013, Scientific Reports.

[136]  G. R. Reddy,et al.  Calcium phosphate nanoparticle prepared with foot and mouth disease virus P1-3CD gene construct protects mice and guinea pigs against the challenge virus. , 2009, Veterinary microbiology.

[137]  Mithat Gönen,et al.  Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection , 2017, Nature.

[138]  A. Balato,et al.  Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. , 2009, The Journal of investigative dermatology.

[139]  Ennio De Gregorio,et al.  The path to a successful vaccine adjuvant--'the long and winding road'. , 2009, Drug discovery today.

[140]  B. Yvonnet,et al.  Simultaneous administration of diphtheria-tetanus-pertussis-polio and hepatitis B vaccines in a simplified immunization program: immune response to diphtheria toxoid, tetanus toxoid, pertussis, and hepatitis B surface antigen , 1986, Infection and immunity.

[141]  Xia Li,et al.  Biodegradable Metal Ion-Doped Mesoporous Silica Nanospheres Stimulate Anticancer Th1 Immune Response in Vivo. , 2017, ACS applied materials & interfaces.

[142]  Jie Li,et al.  Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 , 2004, The Journal of Immunology.

[143]  M. Guenounou,et al.  Involvement of toll-like receptor 4 in the inflammatory reaction induced by hydroxyapatite particles. , 2007, Biomaterials.

[144]  Y. Sogo,et al.  Simple synthesis route of mesoporous AlOOH nanofibers to enhance immune responses , 2013 .

[145]  C. J. Clements,et al.  The global impact of vaccines containing aluminium adjuvants. , 2002, Vaccine.

[146]  Dong Chen,et al.  The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function. , 2010, Biomaterials.

[147]  Jeffrey A. Hubbell,et al.  Materials engineering for immunomodulation , 2009, Nature.

[148]  F. Martinon,et al.  Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.

[149]  XinRan Li,et al.  Relationship between the size of nanoparticles and their adjuvant activity: data from a study with an improved experimental design. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[150]  J. Sprent,et al.  T Cell Death and Memory , 2001, Science.

[151]  A. Oyane,et al.  Ascorbate-apatite composite and ascorbate-FGF-2-apatite composite layers formed on external fixation rods and their effects on cell activity in vitro. , 2009, Acta Biomaterialia.

[152]  Ping Zhang,et al.  Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity , 2011, Nature Medicine.

[153]  S. Gabrielsson,et al.  Adjuvant properties of mesoporous silica particles tune the development of effector T cells. , 2012, Small.

[154]  Parul Gupta,et al.  ZnO nanoparticles induced adjuvant effect via toll-like receptors and Src signaling in Balb/c mice. , 2014, Toxicology letters.

[155]  T. Ohno,et al.  Rod-shaped and substituted hydroxyapatite nanoparticles stimulating type 1 and 2 cytokine secretion. , 2016, Colloids and surfaces. B, Biointerfaces.

[156]  J. Mannhalter,et al.  Humoral and cellular immunity induced by antigens adjuvanted with colloidal iron hydroxide. , 1999, Vaccine.

[157]  K. Leong,et al.  Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes. , 2012, Nature materials.

[158]  S. Reed,et al.  Key roles of adjuvants in modern vaccines , 2013, Nature Medicine.

[159]  M. Leslie Solution to vaccine mystery starts to crystallize. , 2013, Science.

[160]  R. Edelman Survey of human-use adjuvants , 2003, Expert review of vaccines.

[161]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[162]  P. Minor Live attenuated vaccines: Historical successes and current challenges. , 2015, Virology.

[163]  Mithat Gönen,et al.  Clinical translation of an ultrasmall inorganic optical-PET imaging nanoparticle probe , 2014, Science Translational Medicine.

[164]  Yanli Zhao,et al.  Multifunctional Mesoporous Silica Nanoparticles for Cancer‐Targeted and Controlled Drug Delivery , 2012 .

[165]  Y. Sogo,et al.  Hollow ZnO Nanospheres Enhance Anticancer Immunity by Promoting CD4+ and CD8+ T Cell Populations In Vivo. , 2017, Small.

[166]  Lili Qin,et al.  Signalling pathways involved in the activation of dendritic cells by layered double hydroxide nanoparticles. , 2010, Biomaterials.

[167]  Lin Zeng,et al.  The use of a gold nanoparticle-based adjuvant to improve the therapeutic efficacy of hNgR-Fc protein immunization in spinal cord-injured rats. , 2011, Biomaterials.

[168]  R. Rappuoli,et al.  Vaccinology at the beginning of the 21st century , 2005, Current Opinion in Immunology.

[169]  M. Morlock,et al.  Proinflammatory and osteoclastogenic effects of beta-tricalciumphosphate and hydroxyapatite particles on human mononuclear cells in vitro. , 2009, Biomaterials.

[170]  N. Mantis,et al.  Immunization of mice with peptomers covalently coupled to aluminum oxide nanoparticles. , 1999, Vaccine.

[171]  W. Wu,et al.  Mechanisms of adjuvancy: I--Metal oxides as adjuvants. , 1997, Vaccine.

[172]  R. Schreiber,et al.  Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.

[173]  K. Ishii,et al.  Optimization of physiological properties of hydroxyapatite as a vaccine adjuvant. , 2016, Vaccine.

[174]  R. Bomford The comparative selectivity of adjuvants for humoral and cell-mediated immunity. II. Effect on delayed-type hypersensitivity in the mouse and guinea pig, and cell-mediated immunity to tumour antigens in the mouse of Freund's incomplete and complete adjuvants, alhydrogel, Corynebacterium parvum, Bord , 1980, Clinical and experimental immunology.

[175]  T. Ohno,et al.  Hollow Structure Improved Anti-Cancer Immunity of Mesoporous Silica Nanospheres In Vivo. , 2016, Small.

[176]  M. Guenounou,et al.  Influence of the zinc concentration of sol-gel derived zinc substituted hydroxyapatite on cytokine production by human monocytes in vitro. , 2006, Biomaterials.

[177]  T. Deerinck,et al.  Quantum Dots for Tracking Dendritic Cells and Priming an Immune Response In Vitro and In Vivo , 2008, PloS one.

[178]  Yufang Zhu,et al.  Binding of CpG oligodeoxynucleotides to mesoporous silica nanoparticles for enhancing delivery efficiency , 2015 .

[179]  H. Aggerbeck,et al.  Adjuvanticity of aluminium hydroxide and calcium phosphate in diphtheria-tetanus vaccines--I. , 1995, Vaccine.

[180]  V E Schijns,et al.  Immunological concepts of vaccine adjuvant activity. , 2000, Current opinion in immunology.

[181]  T. Ohno,et al.  Particle-size-dependent toxicity and immunogenic activity of mesoporous silica-based adjuvants for tumor immunotherapy. , 2013, Acta biomaterialia.

[182]  E. B. Lindblad Aluminium compounds for use in vaccines , 2004, Immunology and cell biology.

[183]  Y. Liu,et al.  The effect of Gd@C82(OH)22 nanoparticles on the release of Th1/Th2 cytokines and induction of TNF-alpha mediated cellular immunity. , 2009, Biomaterials.

[184]  C. Coban,et al.  DNA released from dying host cells mediates aluminum adjuvant activity , 2011, Nature Medicine.

[185]  A. Taniguchi,et al.  Hierarchically porous, and Cu- and Zn-containing γ-AlOOH mesostrands as adjuvants for cancer immunotherapy , 2017, Scientific Reports.